hbi-3000
Small moleculeexperimental
HBI-3000 is an experimental drug candidate that is currently in phase II of human clinical trials as an antiarrhythmic agent. Clinical investigation will test the safety and efficacy of HBI-3000 as a treatment for both atrial and ventricular arrhythmias. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 17, 2017 (NCT03397641)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHBI-3000 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04680026 | Phase 2 | Jan 31, 2021 | HUYA Bioscience International |
| NCT04650542 | Phase 1 | Dec 31, 2020 | HUYA Bioscience International, Nucleus Network Ltd |
| NCT03397641 | Phase 1 | Oct 17, 2017 | HUYA Bioscience International, Quotient |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| HUYA Bioscience International | For profit | 3 | 3 | 2 | 2017 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2020 |
| Quotient | For profit | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1